The FDA-approved labeling for these medications does not specifically address international travel, but general principles for transporting temperature-sensitive biologics apply
Ung lc no? , bn hy da vo thnh phn a ra quyt nh
293 A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors (2019)
Ya Yakc Karnitin Nelerde Bulunur
However, secondary patents covering formulations and dosing methods extend protection through 2031-2033 depending on the specific product
Possible side effects may include injection-site irritation, mild fluid retention, headache, fatigue, appetite changes, or joint discomfort